MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326900 | Name: Eprodisate disodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eprodisate, also known as 3-PDS; NC-503; 3PDS, is an orally available disodium salt form of eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis. Upon administration, eprodisate competitively binds to the glycosaminoglycan binding sites on serum amyloid A (SAA), which inhibits the formation of the glycosaminoglycan-amyloid fibril aggregate. This prevents the formation of amyloid deposits in certain organs, especially the kidneys, in AA amyloidosis.

Chemical Structure

Eprodisate disodium
Eprodisate disodium
CAS#36589-58-9 (disodium)

Theoretical Analysis

MedKoo Cat#: 326900

Name: Eprodisate disodium

CAS#: 36589-58-9 (disodium)

Chemical Formula: C3H6Na2O6S2

Exact Mass: 0.0000

Molecular Weight: 248.17

Elemental Analysis: C, 14.52; H, 2.44; Na, 18.53; O, 38.68; S, 25.84

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
21668-77-9 (free base) 36589-58-9 (disodium)
Synonym
Eprodisate Sodium; Kiacta; NC-503; NC503; NC 503; NSC-240395; NSC240395; NSC 240395; NSC-760403; NSC 760403; NSC760403;
IUPAC/Chemical Name
1,3-Propanedisulfonic acid, disodium salt
InChi Key
DKGJFKPIUSHDIT-UHFFFAOYSA-L
InChi Code
InChI=1S/C3H8O6S2.2Na/c4-10(5,6)2-1-3-11(7,8)9;;/h1-3H2,(H,4,5,6)(H,7,8,9);;/q;2*+1/p-2
SMILES Code
O=S(CCCS(=O)([O-])=O)([O-])=O.[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 21668-77-9(Eprodisate) 36589-58-9(Eprodisate Sodium)

Preparing Stock Solutions

The following data is based on the product molecular weight 248.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014 Oct 29;6:369-77. doi: 10.2147/CLEP.S39981. eCollection 2014. Review. PubMed PMID: 25378951; PubMed Central PMCID: PMC4218891. 2: Wang P, Ding K. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease. Protein Pept Lett. 2014;21(10):1048-56. Review. PubMed PMID: 24975673. 3: Rumjon A, Coats T, Javaid MM. Review of eprodisate for the treatment of renal disease in AA amyloidosis. Int J Nephrol Renovasc Dis. 2012;5:37-43. doi: 10.2147/IJNRD.S19165. Epub 2012 Feb 24. PubMed PMID: 22427728; PubMed Central PMCID: PMC3304340. 4: Martínez-Valle F, Gironella-Mesa M, Solans-Laqué R. [New trends in the treatment of amyloidosis]. Med Clin (Barc). 2012 May 26;138(15):667-72. doi: 10.1016/j.medcli.2011.09.032. Epub 2011 Dec 22. Review. Spanish. PubMed PMID: 22197598. 5: Herrera GA, Teng J, Turbat-Herrera EA. Renal amyloidosis: current views on pathogenesis and impact on diagnosis. Contrib Nephrol. 2011;169:232-46. doi: 10.1159/000314795. Epub 2011 Jan 20. PubMed PMID: 21252523. 6: Zdrojewski Z. [Amyloidosis in rheumatic diseases]. Ann Acad Med Stetin. 2010;56 Suppl 1:7-15. Review. Polish. PubMed PMID: 21365934. 7: Blank N, Lorenz HM. [Diagnostics and therapy of AA amyloidosis]. Pathologe. 2009 May;30(3):219-25. doi: 10.1007/s00292-009-1140-5. Review. German. PubMed PMID: 19333604. 8: Manenti L, Tansinda P, Vaglio A. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin Pharmacother. 2008 Aug;9(12):2175-80. doi: 10.1517/14656566.9.12.2175 . Review. PubMed PMID: 18671471. 9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51. PubMed PMID: 18597009. 10: Pani A. [A new treatment of renal disease in AA amyloidosis...and not only that?]. G Ital Nefrol. 2008 Jan-Feb;25(1):12. Italian. PubMed PMID: 18264913. 11: Rule AD, Leung N. Eprodisate slows the progression of renal disease in patients with AA amyloidosis. Nat Clin Pract Nephrol. 2007 Nov;3(11):592-3. Epub 2007 Sep 18. PubMed PMID: 17876351. 12: Manenti L, Tansinda P, Vaglio A. Eprodisate in AA amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1153; author reply 1153-4. PubMed PMID: 17855678. 13: Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gül A, Merlini G, Wiland P, Ozdogan H, Gorevic PD, Maïz HB, Benson MD, Direskeneli H, Kaarela K, Garceau D, Hauck W, Van Rijswijk MH. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2007 Jun;14(2):133-40. Erratum in: Amyloid. 2007 Dec;14(4):325. PubMed PMID: 17577686. 14: Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2413-5. PubMed PMID: 17554124. 15: Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. PubMed PMID: 17554116. 16: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PubMed PMID: 17520107. 17: Grateau G, Valleix S, Callard P. [Multisystemic amyloidosis in 2007]. Rev Med Interne. 2007 May;28(5):281-3. Epub 2007 Jan 26. Review. French. PubMed PMID: 17291633.